Enhancing CAR-T Cell Therapy with CRISPR for Blood Cancer Treatment

Blood cancer cases, including lymphoma, leukemia, and multiple myeloma, remain a leading cause of cancer worldwide, with an estimated 1.24 million people being affected annually.Every year, approximately 700,000 people die from blood cancer, highlighting the urgent need for more effective treatments.Currently, chimeric antigen receptor (CAR) T-cell therapy is the most advanced treatment for these cases.CAR-T cell therapy involves genetically modifying patients' T-cells to target and destroy cancer cells.Despite its success, CAR-T cell therapy faces challenges, including side effects like cytokine release syndrome and limited effectiveness against some blood cancers.CRISPR gene editing has the ability to overcome these limitations and strengthen CAR-T cell therapy, offering patients a potential solution by enhancing efficiency and precision in targeting cancer cells.Various types of CRISPR-Cas applications can be used in CAR-T cells to create effective treatment options, such as the creation of "off-the-shelf" allogeneic cells.This review will discuss current issues of blood cancer treatments and how CRISPR can be utilized in next-generation CAR-T cell therapies to improve T-cell engineering, strengthen resistance to tumors, and incorporate safety mechanisms to reduce side effects.